Notice of Availability of Environmental Assessment and Finding of No Significant Impact for License Amendment for Exxonmobil Biomedical Sciences, Inc.'s Facility in Annandale, NJ, 6469-6470 [05-2244]

Agencies

• NUCLEAR REGULATORY COMMISSION

[Federal Register Volume 70, Number 24 (Monday, February 7, 2005)]
[Notices]
[Pages 6469-6470]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-2244]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-17541]


Notice of Availability of Environmental Assessment and Finding of 
No Significant Impact for License Amendment for Exxonmobil Biomedical 
Sciences, Inc.'s Facility in Annandale, NJ

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Betsy Ullrich, Commercial and R&D 
Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale 
Road, King of Prussia, Pennsylvania, 19406, telephone (610) 337-5040, 
fax (610) 337-5269; or by email: EXU@NRC.GOV.

SUPPLEMENTARY INFORMATION: 

I. Introduction

    The Nuclear Regulatory Commission (NRC) is issuing a license 
amendment to Exxonmobil Biomedical Sciences, Inc. for Materials License 
No. 29-19396-01, to authorize release of its facility in Annandale, New 
Jersey for unrestricted use. NRC has prepared an Environmental 
Assessment (EA) in support of this action in accordance with the 
requirements of 10 CFR Part 51. Based on the EA, the NRC has concluded 
that a Finding of No Significant Impact (FONSI) is appropriate. The 
amendment will be issued following the publication of this Notice.

II. EA Summary

    The purpose of the action is to authorize the release of the 
licensee's Annandale, New Jersey facility for unrestricted use. 
Exxonmobil Biomedical Sciences, Inc. was authorized by NRC from 
December 14, 1999, to use radioactive materials for research and 
development purposes at the site. On October 25, 2004, Exxonmobil 
Biomedical Sciences, Inc. requested that NRC release the facility for 
unrestricted use. Exxonmobil Biomedical Sciences, Inc. has conducted 
surveys of the facility and provided information to the NRC to 
demonstrate that the site meets the license termination criteria in 
Subpart E of 10 CFR Part 20 for unrestricted use.
    The NRC staff has prepared an EA in support of the license 
amendment. The facility was remediated and surveyed prior to the 
licensee requesting the license amendment. The NRC staff has reviewed 
the information and final status survey submitted by Exxonmobil 
Biomedical Sciences, Inc. Based on its review, the staff has determined 
that there are no additional remediation activities necessary to 
complete the proposed action. Therefore, the staff considered the 
impact of the residual radioactivity at the facility and concluded that 
since the residual radioactivity meets the requirements in Subpart E of 
10 CFR Part 20, a Finding of No Significant Impact is appropriate.

III. Finding of No Significant Impact

    The staff has prepared the EA (summarized above) in support of the 
license amendment to terminate the license and release the facility for 
unrestricted use. The NRC staff has evaluated Exxonmobil Biomedical 
Sciences, Inc.''s request and the results of the surveys and has 
concluded that the completed action complies with the criteria in 
Subpart E of 10 CFR Part 20. The staff has found that the environmental 
impacts from the action are bounded by the impacts evaluated by NUREG-
1496, Volumes 1-3, ``Generic Environmental Impact Statement in Support 
of Rulemaking on Radiological Criteria for License Termination of NRC-
Licensed Facilities'' (ML042310492, ML042320379, and ML042330385). On 
the basis of the EA, the NRC has concluded that the environmental 
impacts from the action are expected to be insignificant and has 
determined not to prepare an environmental impact statement for the 
action.

IV. Further Information

    Documents related to this action, including the application for the 
license amendment and supporting documentation, are available 
electronically at the NRC's Electronic Reading Room at https://
www.nrc.gov/reading-rm/adams.html. From this site, you can access the 
NRC's Agencywide Document Access and Management System (ADAMS), which 
provides text and image files of NRC's public documents. The ADAMS 
accession numbers for the documents related to this Notice are: 
Environmental Assessment Related to an Amendment of U.S. Nuclear 
Regulatory Commission Materials License No. 29-19396-01 ML050280058; 
and the Radiological Decommissioning Report, ExxonMobil Biomedical 
Sciences, Inc., 1545 Route 22 East, Annandale, New Jersey, October 24, 
2004 (ML043100336). Please note that on October 25, 2004, the NRC 
terminated public access to ADAMS and initiated an additional security 
review of publicly available documents to ensure that potentially 
sensitive information is removed from

[[Page 6470]]

the ADAMS database accessible through the ADAMS web site. Interested 
members of the public may obtain copies of the reference documents for 
review and or copying by contacting the Public Document Room pending 
resumption of public access to ADAMS. The NRC Public Documents Room is 
located at NRC Headquarters in Rockville, Maryland, and can be 
contacted at (800) 397-4209 or (301) 415-4737, or by email to 
pdr@nrc.gov. The PDR reproduction contractor will copy documents for a 
fee. The PDR is open from 7:45 a.m. to 4:15 p.m., Monday through 
Friday, except on Federal holidays.

    Dated at King of Prussia, Pennsylvania, this 28th day of 
January, 2005.

    For the Nuclear Regulatory Commission.
James Dwyer,
Chief, Commercial and R&D Branch, Division of Nuclear Materials Safety, 
Region I.
[FR Doc. 05-2244 Filed 2-4-05; 8:45 am]
BILLING CODE 7590-01-P